Hépatite D:oubliée mais pas disparue [Hepatitis D: forgotten but not gone].


Autoria(s): Moradpour D.; Negro F.
Data(s)

2010

Resumo

Hepatitis D virus (HDV) is a subviral agent which depends on the envelope proteins (HBsAg) of hepatitis B virus (HBV). Therefore, hepatitis D is observed only in patients infected with HBV. Chronic hepatitis D is the least frequent albeit most severe form of chronic viral hepatitis. A resurgence of chronic hepatitis D has been observed in Northern and Central Europe, mainly due to immigration of patients from regions with high prevalence. Every HBsAg-positive patient should be screened for concurrent HDV infection. Standard treatment consists of pegylated interferon-alpha for at least one year. Sustained virological response rates are approximately 20%. Liver transplantation should be considered in patients with advanced cirrhosis or limited hepatocellular carcinoma. Preventive measures for hepatitis D are the same as for hepatitis B.

Identificador

http://serval.unil.ch/?id=serval:BIB_28ED6BBD6620

isbn:1660-9379[print], 1660-9379[linking]

pmid:20939399

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 6, no. 261, pp. 1656-1659

Palavras-Chave #Antiviral Agents/therapeutic use; European Union/statistics & numerical data; Hepatitis B/complications; Hepatitis D/diagnosis; Hepatitis D/epidemiology; Hepatitis D, Chronic; Hepatitis Delta Virus/isolation & purification; Humans; Interferon Alfa-2a/therapeutic use; Interferon Alfa-2b/therapeutic use; Liver Transplantation; Polyethylene Glycols/therapeutic use; Prevalence; World Health
Tipo

info:eu-repo/semantics/article

article